Therapeutic Response

EGFR oncogenic variants status confers therapeutic sensitivity to Bevacizumab in combination with Erlotinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Bevacizumab 15mg/kg Therapy - 21 days. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved bevacizumab in combination with erlotinib for reimbursement as a treatment option for the first-line treatment of adult patients with unresectable advanced, metastatic, or recurrent non-small cell lung cancer with EGFR activating variants.